This is an extension study for patients who have previously completed Idenix Study
NV-02B-003. This study is being conducted to compare the safety and effectiveness of
treatment beyond 1 year of telbivudine and telbivudine combined with lamivudine, a drug
currently approved for the treatment of hepatitis B.
- Patient has completed protocol NV-02B-003 without a serious adverse event attributed
to study drug
- Patient remains seropositive for hepatitis B surface antigen (HBsAg)
Other protocol-defined inclusion criteria may apply.
- Patient is pregnant or breast-feeding
- Patient has signs of decompensated chronic hepatitis B
Other protocol-defined exclusion criteria may apply.